Based on the findings of this study, we hypothesized that FOXD3-AS1 may affect the prognosis by regulating the immune microenvironment and tumor stemness in GBM and LGG, as well as having the potential to affect the efficacy of immunotherapy. Here, FOXD3 is linked to glioblastoma.